Cases
Indivior PLC (INVVY)
Securities Class Action
Overview
Overview
- Date:
- 4/10/2019
- Company Name:
- Indivior PLC
- Stock Symbol:
- INVVY
- Status:
- Closed/Complete
NEW YORK, April 10, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against Indivior PLC (Other OTC: INVVY). Our investigation concerns whether Indivior has violated the federal securities laws and/or engaged in other unlawful business practices.
On April 10, 2019, the U.S. Department of Justice charged Indivior with organizing a multibillion-dollar fraud to drive up sales of Suboxone Film, an opioid-addiction treatment. Bloomberg published an article detailing the charges against Indivior, noting that according to the Justice Department, “Indivior misled doctors and government health programs into believing that the drug, Suboxone Film, was safer and less likely to be abused than rivals…” The article went on to explain, “Prosecutors said that Indivior marketed Suboxone in a way that allowed some patients to misuse the drug, and did little to stop such practices.”
On this news, Indivior’s share price fell by more than 70%, closing at $2.30 per share on April 10, 2019.
If you purchased or otherwise acquired Indivior shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On April 10, 2019, the U.S. Department of Justice charged Indivior with organizing a multibillion-dollar fraud to drive up sales of Suboxone Film, an opioid-addiction treatment. Bloomberg published an article detailing the charges against Indivior, noting that according to the Justice Department, “Indivior misled doctors and government health programs into believing that the drug, Suboxone Film, was safer and less likely to be abused than rivals…” The article went on to explain, “Prosecutors said that Indivior marketed Suboxone in a way that allowed some patients to misuse the drug, and did little to stop such practices.”
On this news, Indivior’s share price fell by more than 70%, closing at $2.30 per share on April 10, 2019.
If you purchased or otherwise acquired Indivior shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.